Kymera Therapeutics Aktie
WKN DE: A2QBSH / ISIN: US5015751044
09.07.2024 19:30:00
|
Why Kymera Therapeutics Stock Is Soaring Today
Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis.Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advancement of the drug into pivotal testing. The French drugmaker's decision came on the heels of a positive preliminary review of KT-474's safety and efficacy data by an Independent Data Review Committee. Anything that could potentially speed up the timeline for getting a product to market is great news for a clinical-stage biopharma company. Investors are justifiably thrilled with Sanofi's decision to expand phase 2 studies of KT-474.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Kymera Therapeutics Inc Registered Shsmehr Nachrichten
30.10.24 |
Ausblick: Kymera Therapeutics stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Kymera Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Kymera Therapeutics Inc Registered Shs | 23,69 | -10,13% |
|